Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenABCWY dosing schedule study in healthy adolescents
2021-001670-33Phase 2Active
- Sponsor
- GSK
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Meningococcal ABCYW vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Percentage of participants with hSBA titers at or above LLOQ for serogroup B indicator strains. Started Oct 2021; status: active.
02
Drugs
Meningococcal ABCYW vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2021-001670-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001670-33.